Abeona Therapeutics Inc. (ABEO): Price and Financial Metrics

Abeona Therapeutics Inc. (ABEO): $7.76

0.86 (+12.46%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

ABEO Price/Volume Stats

Current price $7.76 52-week high $7.87
Prev. close $6.90 52-week low $2.24
Day low $6.92 Volume 1,120,627
Day high $7.87 Avg. volume 315,924
50-day MA $5.55 Dividend yield N/A
200-day MA $4.39 Market Cap 192.24M

ABEO Stock Price Chart Interactive Chart >

ABEO POWR Grades

  • ABEO scores best on the Sentiment dimension, with a Sentiment rank ahead of 92.59% of US stocks.
  • ABEO's strongest trending metric is Growth; it's been moving down over the last 26 weeks.
  • ABEO ranks lowest in Growth; there it ranks in the 17th percentile.

ABEO Stock Summary

  • ABEO's price/sales ratio is 39.92; that's higher than the P/S ratio of 96.09% of US stocks.
  • With a year-over-year growth in debt of -31.37%, ABEONA THERAPEUTICS INC's debt growth rate surpasses merely 10.38% of about US stocks.
  • ABEONA THERAPEUTICS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -50.8%, greater than the shareholder yield of just 7.89% of stocks in our set.
  • Stocks that are quantitatively similar to ABEO, based on their financial statements, market capitalization, and price volatility, are SABS, SRZN, SENS, ADVM, and FULC.
  • Visit ABEO's SEC page to see the company's official filings. To visit the company's web site, go to www.abeonatherapeutics.com.

ABEO Valuation Summary

  • In comparison to the median Healthcare stock, ABEO's price/earnings ratio is 110.98% lower, now standing at -3.2.
  • ABEO's EV/EBIT ratio has moved up 13.2 over the prior 243 months.

Below are key valuation metrics over time for ABEO.

Stock Date P/S P/B P/E EV/EBIT
ABEO 2023-12-29 34.8 5.6 -3.2 -3.3
ABEO 2023-12-28 35.7 5.8 -3.3 -3.3
ABEO 2023-12-27 35.5 5.8 -3.3 -3.3
ABEO 2023-12-26 35.3 5.7 -3.3 -3.3
ABEO 2023-12-22 34.5 5.6 -3.2 -3.2
ABEO 2023-12-21 33.2 5.4 -3.1 -3.1

ABEO Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at 15.26%.
  • The 4 year price growth rate now stands at -60.81%.
  • Its 2 year cash and equivalents growth rate is now at -34.71%.
Over the past 15 months, ABEO's revenue has gone down $5,654,000.

The table below shows ABEO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 4.346 -59.748 -89.035
2022-06-30 4.346 -63.291 -86.595
2022-03-31 3.346 -65.767 -89.725
2021-12-31 3 -65.665 -84.936
2021-09-30 3 -37.018 -54.081
2021-06-30 10 -37.386 -54.274

ABEO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ABEO has a Quality Grade of C, ranking ahead of 61.27% of graded US stocks.
  • ABEO's asset turnover comes in at 0.069 -- ranking 293rd of 682 Pharmaceutical Products stocks.
  • MCRB, NVAX, and VXRT are the stocks whose asset turnover ratios are most correlated with ABEO.

The table below shows ABEO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.069 1 -0.763
2021-03-31 0.065 1 -0.616
2020-12-31 0.062 1 -1.011
2020-09-30 0.039 1 -1.361
2020-06-30 0.000 NA -2.242
2020-03-31 0.000 NA -3.902

ABEO Price Target

For more insight on analysts targets of ABEO, see our ABEO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.00 Average Broker Recommendation 1.33 (Strong Buy)

Abeona Therapeutics Inc. (ABEO) Company Bio


Abeona Therapeutics Inc. focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company iwas founded n 1989 and is based in Dallas, Texas.


ABEO Latest News Stream


Event/Time News Detail
Loading, please wait...

ABEO Latest Social Stream


Loading social stream, please wait...

View Full ABEO Social Stream

Latest ABEO News From Around the Web

Below are the latest news stories about ABEONA THERAPEUTICS INC that investors may wish to consider to help them evaluate ABEO as an investment opportunity.

Those who invested in Abeona Therapeutics (NASDAQ:ABEO) a year ago are up 98%

These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do...

Yahoo | December 23, 2023

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On December 14, 2023, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to four individuals hired by Abeona, which equity awards relate to, in the

Yahoo | December 15, 2023

ABEO: BLA for Pz-Cel (EB-101) Accepted with Priority Review; PDUFA Date of May 25, 2024…

By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT Business Update BLA Accepted with Priority Review; PDUFA Action Date of May 25, 2024 On November 27, 2023, Abeona Therapeutics, Inc. (NASDAQ:ABEO) announced that the U.S. Food and Drug Administration (FDA) has accepted with Priority Review the Biologics License Application (BLA) to seek approval for prademagene zamikeracel

Yahoo | November 29, 2023

Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

- PDUFA target action date is May 25, 2024 - - FDA does not currently plan to hold Advisory Committee meeting for pz-cel BLA - CLEVELAND, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Biologics License Application (BLA) for pz-cel (prademagene zamikeracel), Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets for the treatment of pat

Yahoo | November 27, 2023

Abeona Therapeutics Inc. (NASDAQ:ABEO) Q3 2023 Earnings Call Transcript

Abeona Therapeutics Inc. (NASDAQ:ABEO) Q3 2023 Earnings Call Transcript November 16, 2023 Operator: Greetings, and welcome to the Abeona Therapeutics Third Quarter 2023 Conference Call. [Operator Instructions]. Please note this conference is being recorded. I will now turn the conference over to your host, Mr. Greg Gin. Sir, you may begin. Greg Gin: Thank you, […]

Yahoo | November 17, 2023

Read More 'ABEO' Stories Here

ABEO Price Returns

1-mo 90.66%
3-mo 66.52%
6-mo 85.20%
1-year 220.66%
3-year -86.85%
5-year -95.92%
YTD 54.89%
2023 62.66%
2022 -63.44%
2021 -78.54%
2020 -51.99%
2019 -54.20%

Continue Researching ABEO

Want to see what other sources are saying about Abeona Therapeutics Inc's financials and stock price? Try the links below:

Abeona Therapeutics Inc (ABEO) Stock Price | Nasdaq
Abeona Therapeutics Inc (ABEO) Stock Quote, History and News - Yahoo Finance
Abeona Therapeutics Inc (ABEO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!